Akeso Inc. has announced the enrollment of the first patient in its Phase III clinical trial (AK112-312/HARMONi-GI6) evaluating the efficacy of ivonescimab as a first-line treatment for advanced metastatic colorectal cancer. This trial is a pivotal step in addressing the unmet clinical needs for patients with this condition. Previous Phase II data, presented at the 2024 European Society for Medical Oncology Congress, demonstrated promising anti-tumor activity of ivonescimab in combination with chemotherapy, showing an overall response rate of 81.8% and a disease control rate of 100%. The ongoing Phase III trial aims to further validate these findings and potentially offer a novel immunotherapy treatment option for patients with microsatellite stable or proficient mismatch repair-type metastatic colorectal cancer, a group representing up to 95% of such cases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。